Breaking News
Get 60% Off 0
Cyber Monday Deal: Up to 60% off InvestingPro
CLAIM SALE
Close

Innate Pharma (IPH)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.35 -0.03    -2.46%
03:50:16 - Delayed Data. Currency in EUR
Type:  Equity
Market:  Germany
ISIN:  FR0010331421 
S/N:  A0LCUJ
  • Volume: 6
  • Bid/Ask: 1.35 / 1.38
  • Day's Range: 1.35 - 1.35
Innate Pharma 1.35 -0.03 -2.46%

Innate Pharma SA Company Profile

 
Get an in-depth profile of Innate Pharma, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

191

Equity Type

ORD

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Contact Information

Address 117, Avenue de Luminy BP 30191
Marseille, 13009
France
Phone 33 4 30 30 30 30
Fax 33 4 30 30 30 00

Top Executives

Name Age Since Title
Mailys Ferrere 59 2017 Member of Supervisory Board
Gilles Brisson 72 2007 Independent Member of Supervisory Board
Irina Staatz-Granzer 64 2009 Independent Chairwoman of Supervisory Board
Olivier Martinez 54 2010 Member of Supervisory Board
Jean-Yves Blay 62 2017 Independent Member of Supervisory Board
Veronique Chabernaud 63 2015 Independent Member of Supervisory Board
Miriam Merad - 2018 Chairman of Strategic Advisory Board
Pascale Boissel 58 2020 Independent Vice Chairperson of the Supervisory Board
Mario Sznol 66 2018 Strategic Advisory Board Member
Aurelien Marabelle - 2018 Strategic Advisory Board Member
Sally Louise Bennett 52 2022 Independent Supervisory Board Member
Diane J. Mathis - 2024 Strategic Advisory Board
Katy Rezvani - 2024 Strategic Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IPH Comments

Write your thoughts about Innate Pharma SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Arth Dlg
Arth Dlg Mar 29, 2023 3:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any trends ideas? I see their revenue increasing but looks like they lack of cashflow
Yassine Mous
Yassine Mous Dec 19, 2022 1:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
in the moon
Roel Munt
CrustyCrabz Nov 13, 2020 7:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
They got a lawsuit coming, probably will lower in the future
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email